Atezolizumab-Induced Bell’s Palsy in a Patient With Small Cell Lung Cancer

Immune checkpoint inhibitors are rapidly becoming popular therapeutic options for patients suffering from a number of malignancies. Atezolizumab is a programmed cell death ligand-1 inhibitor, and binding to this ligand decreases the ability of tumor cells to evade the immune system, resulting in sel...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Investig Med High Impact Case Rep
Egile Nagusiak: Kichloo, Asim, Albosta, Michael Stanley, Jamal, Shakeel M., Aljadah, Michael, Wani, Farah, Selene, Insija, Singh, Jagmeet, Taj, Asma
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2020
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7557644/
https://ncbi.nlm.nih.gov/pubmed/33047629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2324709620965010
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak